{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "m__pwJZAJxr1"
      },
      "source": [
        "# Executive Summary\n",
        "\n",
        "CVS Health Corporation (NYSE: CVS) is a leading healthcare company with a diversified business spanning retail pharmacies, insurance (Aetna), and pharmacy benefit management (Caremark). In 2024, CVS generated roughly \\$372.8 billion in revenue with a net income of \\$4.6 billion. This makes CVS the second-largest healthcare company globally, behind only UnitedHealth Group. The company is leveraging its expansive footprint of \\~9,100 retail pharmacies and extensive healthcare assets to transform into an integrated health solutions provider. Our analysis finds that CVS is strategically positioned in an evolving industry that is shifting toward convenient, value-based care delivery, which plays to CVS's strengths.\n",
        "\n",
        "Despite short-term headwinds, CVS's recent performance has been solid. For example, Q1 2025 revenue grew \\~7% year-over-year and adjusted operating income jumped \\~55%. Management projects steady earnings growth (targeting \\~\\$9.00 adjusted EPS in 2024 and \\~\\$10.00 in 2025) as recent acquisitions are integrated. The stock currently trades at a single-digit forward P/E (\\~8x 2025 earnings), suggesting a potential value opportunity. We see a favorable risk-reward profile given CVS’s scale, stable cash flows, and opportunities to capture greater market share as weaker competitors retreat.\n",
        "\n",
        "Recommendation: We recommend a bullish options strategy to capitalize on CVS's upside potential. Specifically, buying call options expiring in late August 2025 (around the next earnings release) can provide leveraged exposure to a positive earnings surprise or upward re-rating of the stock. This approach limits downside to the premium paid, while offering significant upside if our thesis plays out. In the following sections, we detail the industry backdrop, CVS's company outlook, competitive landscape, key investment thesis points, and the calculations supporting our option strategy."
      ],
      "id": "m__pwJZAJxr1"
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "31zkaFUFJxr3"
      },
      "source": [
        "# Industry Analysis\n",
        "\n",
        "The healthcare and pharmacy industry is undergoing rapid transformation. Consumer expectations and policy changes are driving care delivery to become more patient-centric, convenient, and value-based. According to a McKinsey report, the future of healthcare will increasingly feature virtual and outpatient services, integration of care across settings, and risk-sharing payment models. In practical terms, this means services are moving out of hospitals into clinics, retail pharmacies, and even the home. Retail health players like CVS are poised to play a larger role in primary care and chronic disease management, leveraging their nationwide presence and data capabilities to provide care in lower-cost settings.\n",
        "\n",
        "Several macro trends underpin this shift:\n",
        "\n",
        "*  Aging Population & Rising Healthcare Demand: As the U.S. population ages, demand for medications and chronic care is increasing. Pharmacies and insurers benefit from higher utilization of prescriptions and medical services. However, payors are emphasizing cost control and outcomes, which fuels the move to value-based care (paying providers for quality/results rather than volume). CVS, with its retail clinics and insurance arm, is adapting to this by focusing on care management and preventative services.\n",
        "Healthcare Spending Growth and Pressure: Healthcare expenditures in the U.S. are at all-time highs (approaching 18-20\\% of GDP) and expected to keep growing. This creates opportunities for companies that can deliver care more efficiently. Integrated models - where insurers, providers, and pharmacies coordinate care - are seen as a way to reduce duplication and lower costs. CVS's vertical integration (pharmacy + insurance + clinics) aligns with this industry direction, as it can streamline patient care and potentially reduce total medical costs.\n",
        "\n",
        "* Regulatory and Pricing Dynamics: The pharmacy sector faces ongoing reimbursement pressure and regulatory scrutiny. Pharmacy Benefit Managers (PBMs) like CVS Caremark are under review for their rebate practices, and retail pharmacies see slim margins due to lower reimbursement rates. At the same time, drug pricing reforms and opioid litigation are significant external factors. (For instance, rival Rite Aid settled opioid claims and ultimately filed for bankruptcy in 2023.) Companies must navigate these pressures through scale and diversification - CVS's scale gives it bargaining power in procurement and an ability to absorb legal/regulatory costs better than smaller peers.\n",
        "\n",
        "* Digital Health and Convenience: The pandemic accelerated telehealth, home delivery of prescriptions, and digital engagement. Consumers now expect to manage health needs online or at local clinics/pharmacies with minimal friction. CVS is investing in digital apps, telemedicine, and home care (via acquisitions like Signify Health) to meet these expectations. McKinsey notes that care is increasingly delivered “in the home” and enabled by technology and data, indicating that CVS's moves into home health and analytics are on-trend.\n",
        "\n",
        "The industry is moving toward integrated, outcome-driven care with an emphasis on convenience. Companies that can offer a one-stop healthcare experience - from insurance coverage to medical advice to prescription fulfillment - are positioned to capture value. CVS's broad portfolio fits this direction, but the company must execute well to overcome margin pressures and new competition in this evolving landscape."
      ],
      "id": "31zkaFUFJxr3"
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Company Background\n",
        "\n",
        "CVS Health has transformed from a traditional drugstore chain into a diversified healthcare conglomerate. CVS now operates through three main segments:\n",
        "* **Pharmacy & Retail:** CVS Pharmacy is one of the largest U.S. pharmacy chains with \\~9,600 locations, filling over one out of every five prescriptions nationwide. Approximately 85\\% of Americans live within 10 miles of a CVS Pharmacy, a testament to its reach. The retail segment also includes health products, over-the-counter medicines, and services like vaccinations and diagnostic testing. CVS's MinuteClinic subsidiary runs 1,100+ in-store health clinics, making it the largest walk-in clinic network in the country. These clinics provide convenient care for minor illnesses, preventive screenings, and are integral to CVS's strategy of offering broader healthcare services in the community.\n",
        "\n",
        "* **Health Care Benefits (Insurance):** In 2018, CVS acquired Aetna, one of the nation's major health insurers, in a landmark $69 billion deal. Aetna provides medical, dental, and pharmacy insurance plans to over 20 million members. This acquisition propelled CVS into managed care, allowing it to combine insurance data with pharmacy capabilities. By owning an insurer, CVS can direct patients to its pharmacies and clinics, and design insurance products that incentivize use of its services. This segment has become a major revenue contributor and strategic asset - CVS can now capture premiums and manage medical costs, not just dispense drugs. However, it also means CVS is exposed to insurance-related challenges (e.g. medical cost trends, Medicare policy changes). Notably, Medicare Advantage is a growth area for Aetna; improved star quality ratings in 2025 have already boosted results.\n",
        "\n",
        "* **Pharmacy Services (PBM):** CVS Caremark is a leading Pharmacy Benefit Manager, administering prescription plans for employers, health plans, and government programs. It processes over a billion prescriptions annually through a network of 68,000+ pharmacies (including CVS's own stores and others). The PBM segment negotiates drug prices with manufacturers, manages formularies, and provides mail-order and specialty pharmacy services. This business gives CVS significant scale in drug purchasing and a wealth of data on utilization. In recent years, Caremark has driven growth via specialty drugs and new client wins, though pricing pressures (as PBMs pass on more savings to clients) are a constant challenge.\n",
        "\n",
        "CVS has made bold acquisitions to expand its care delivery capabilities. In September 2022, CVS announced the purchase of Signify Health, a home healthcare and physician enablement company, for approximately 8 billion dollars. Signify conducts in-home health evaluations and coordinates care for Medicare populations - assets that complement CVS's insurance business by extending care into patients' homes. Shortly after, in February 2023, CVS agreed to acquire Oak Street Health for \\$10.6 billion. Oak Street operates primary care centers for Medicare patients with a value-based care model. This deal (completed in May 2023) adds a network of 169 medical clinics (expected to grow to 300+ by 2026) focused on senior care. CVS's rationale is that owning primary care clinics will drive more Medicare enrollments to Aetna, improve health outcomes, and reduce costly hospital visits - ultimately saving money that benefits Aetna and Caremark. As CEO Karen Lynch stated, “Combining Oak Street Health's platform with CVS Health's unmatched reach will create the premier value-based primary care solution”. These acquisitions, along with the 2014 purchase of Omnicare (long-term care pharmacy) and various clinic initiatives, illustrate CVS's evolution into a health services provider beyond the pharmacy counter.\n",
        "\n",
        "Financial Position: CVS's revenues have grown dramatically with these expansions - rising from 268 billion dollars in 2020 to 322 billion dollars in 2022, and reaching 372.8 billion dollars in 2024 (which includes the Aetna premium revenues). However, operating income and net income have been more volatile, reflecting integration costs and one-time charges. Notably, 2022 net income dropped to 4.2B USD (from 7.9B USD in 2021) due partly to opioid litigation charges and a write-down in the long-term care pharmacy business. In 2023, profitability rebounded modestly to \\$4.614 billion net income. The balance sheet carries a significant debt load (over 50B USD of long-term debt as of 2023) from the Aetna, Signify, and Oak Street deals. CVS has paused share buybacks in recent years to prioritize debt reduction and maintaining its investment-grade credit ratings. Encouragingly, cash flow remains strong, and CVS continues to pay a stable dividend (\\~3% yield).\n",
        "\n",
        "Operational Performance: All three segments contributed to growth in early 2025. In Q1 2025, the Health Services (PBM) segment saw 7.9% revenue growth driven by specialty pharmacy and favorable drug mix. The Retail Pharmacy segment (now renamed “Pharmacy & Consumer Wellness”) grew revenue 11.1% on higher prescription volume - prescriptions filled were up 4.3% overall, as COVID impacts faded and underlying demand increased. However, front-store retail sales softened slightly as consumer spending patterns normalized post-pandemic. The Health Care Benefits segment (Aetna) grew 8.0% in Q1 2025, aided by better Medicare Advantage ratings that boosted payments. Aetna did incur a one-time \\$448 million charge for exiting certain unprofitable ACA exchange markets - in fact, CVS announced it will exit the Affordable Care Act insurance exchanges by 2026 to focus on more profitable lines. This move exemplifies CVS's portfolio strategy: doubling down on areas where it has competitive advantage (Medicare, commercial insurance, pharmacy services) and pulling back from less synergistic, loss-making segments.\n",
        "\n",
        "Overall, CVS's breadth - retail reach, PBM scale, insurance membership - is unparalleled in healthcare aside from UnitedHealth. The company's challenge now is executing on integration: making sure that Aetna members use CVS pharmacies and clinics, that Oak Street clinics improve patient outcomes and reduce costs, and that the whole is greater than the sum of parts. Management's guidance of \\~\\$10 adjusted EPS in 2025 (up from \\~\\$8.80 in 2023) incorporates expectations of synergy and growth from these investments. Achieving this will depend on containing costs (especially integration and interest expenses) and growing revenue across segments in tandem. The company appears confident - CVS reiterated its long-term target of adding 200 basis points to operating income growth through the Oak Street and Signify acquisitions, and projected over $500 million in synergy value to be realized over time. If these goals are met, CVS could see accelerating earnings in the mid to long term."
      ],
      "metadata": {
        "id": "wJWW1ELnKELx"
      },
      "id": "wJWW1ELnKELx"
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "n2ZTPkb9Jxr3"
      },
      "source": [
        "# Competitive Landscape\n",
        "\n",
        "**Walgreens Boots Alliance (WBA):** Walgreens is the second-largest drugstore chain in the U.S. (slightly behind CVS in prescription market share). Walgreens has roughly 9,000 stores and similarly fills a high volume of prescriptions. Like CVS, it has been pivoting toward healthcare services - for example, Walgreens invested in primary care clinic operator VillageMD and specialty pharmacy. However, Walgreens lacks an insurance arm, focusing instead on partnerships. In recent years Walgreens' growth has been challenged by lower retail foot traffic and reimbursement pressure, leading the company to announce cost-cutting and a new CEO in 2023.\n",
        "\n",
        "CVS and Walgreens compete fiercely on pharmacy sales, store footprint, and services like immunizations. Both are also vying to become neighborhood health destinations. CVS's advantage is its integrated insurer and PBM, whereas Walgreens often partners (e.g., with insurance companies or providers) to offer similar services.\n",
        "\n",
        "Financially, Walgreens' revenues (\\~132B USD in 2022) are far smaller than CVS's, and Walgreens' profitability has been under pressure (even posting a net loss in some recent quarters). That said, Walgreens has a strong balance sheet in terms of low debt and continues to be a formidable competitor in retail pharmacy.\n",
        "\n",
        "**Rite Aid:** Rite Aid has historically been the third-largest pharmacy chain, but it has been significantly weakened. In October 2023, Rite Aid filed for Chapter 11 bankruptcy amid mounting debt, declining sales, and opioid lawsuit liabilities. The company has been closing 400-500 stores as part of restructuring, which will leave it with a much smaller footprint (likely under 2,000 stores, concentrated in a few states). Rite Aid’s struggles (including \\$3.3 billion in debt and years of losses) present an opportunity for CVS and Walgreens to capture displaced customers, especially in regions where Rite Aid exits. Indeed, CVS could see a bump in prescription volume as Rite Aid shutters locations (analysts have noted concerns about “pharmacy deserts” if no one steps in, but CVS and others are likely to absorb much of the demand).\n",
        "\n",
        "Overall, Rite Aid is no longer a significant competitive threat to CVS - it is now more a source of market share to be acquired. CVS must execute on converting former Rite Aid patients to CVS customers through community outreach and seamless prescription transfers.\n",
        "\n",
        "**UnitedHealth Group (UNH):** UnitedHealth is the largest healthcare company globally and can be considered both a competitor and, in some segments, a peer model for CVS. UnitedHealth's Optum division directly competes with CVS's Caremark PBM and MinuteClinic/health services. OptumRx is a major PBM, and Optum Health operates clinics, urgent care centers, and physician groups (similar to CVS's clinic and provider strategy). UnitedHealth also has a huge insurance arm (UnitedHealthcare).\n",
        "\n",
        "In many ways, UnitedHealth pioneered the vertically integrated healthcare model that CVS is now emulating. UnitedHealth's revenues (~$324B in 2022) are on par with CVS's, but UNH has enjoyed higher profit margins and a premium valuation in the market. CVS's Aetna unit competes with UnitedHealthcare in selling Medicare Advantage and commercial insurance plans. This is a high-stakes rivalry; for example, both companies seek to enroll seniors in their Medicare plans and then steer those members to their owned providers and pharmacies. CVS's acquisition of Oak Street Health mirrors UnitedHealth's push into primary care through its OptumCare unit.\n",
        "\n",
        "While UnitedHealth is currently the more profitable and diversified company, CVS is one of the few with the assets to challenge it in an integrated approach. The competition here is about who can better manage patient health outcomes at lower cost - success means winning insurance market share and services volume.\n",
        "\n",
        "**Cigna / Express Scripts and Other PBMs:** In the PBM space, the big three are CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (UnitedHealth). Express Scripts is a direct competitor for large employer and government pharmacy benefit contracts. CVS often competes on pricing and service to win these contracts. The PBM industry has come under scrutiny, but scale is a big advantage here: CVS's large network and in-house pharmacies can offer convenient options to clients. Cigna's strategy with Express Scripts is somewhat similar to CVS's vertical model - Cigna sells insurance and uses its PBM to manage drug benefits. CVS's competitive edge in PBM is bolstered by integration (ex. Aetna can utilize Caremark internally) and its proprietary data/analytics to manage utilization.\n",
        "\n",
        "**Amazon and New Entrants:** Amazon's entry into pharmacy and primary care is a developing competitive threat. Amazon acquired online pharmacy PillPack in 2018 and launched Amazon Pharmacy, which delivers prescriptions by mail, potentially drawing price-sensitive or convenience-seeking customers away from brick-and-mortar pharmacies. More recently in February 2023, Amazon completed its \\$3.9 billion acquisition of One Medical, a chain of membership-based primary care clinics. With this move, Amazon signaled intent to integrate virtual care, prescriptions, and in-person clinics under its umbrella - essentially targeting the same integrated care space CVS plays in. For now, CVS's advantage is its vast physical presence and insurance ties, but Amazon's brand and tech prowess mean it could grab younger, tech-savvy customers or negotiate better drug prices (Amazon launched a low-cost generics subscription as well).\n",
        "\n",
        "We view Amazon as a long-term disruptor to monitor; it could pressure pharmacy profit margins industry-wide if it aggressively undercuts on price. CVS is responding by enhancing its own mail pharmacy capabilities and emphasizing clinical services that Amazon (without an insurer yet) may find hard to replicate fully. Other new entrants include Walmart (which has pharmacies and is expanding health clinics in its stores) and insurtech startups partnering with pharmacies - these all add to a dynamic competitive environment.\n",
        "\n",
        "In summary, CVS faces competition on multiple fronts but also benefits from industry consolidation. The retail pharmacy sector is now essentially a duopoly between CVS and Walgreens, especially as Rite Aid shrinks. In healthcare services and insurance, CVS goes up against titans like UnitedHealth and Cigna, requiring CVS to execute strongly on integration and outcomes to win business. Disruptors like Amazon and telehealth companies keep everyone on their toes regarding innovation and pricing. CVS's multi-pronged business model provides resilience - weakness in one area (say retail margins) can be offset by strength in another (insurance premiums or PBM specialty drugs). However, it also means CVS must stay focused across a broad spectrum of operations. The competitive outlook reinforces the need for CVS to leverage its scale, data, and vertical integration to differentiate itself through superior value (lower costs, improved health outcomes, one-stop convenience for consumers)."
      ],
      "id": "n2ZTPkb9Jxr3"
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Key Investment Thesis\n",
        "\n",
        "The bullish investment thesis for CVS Health is based on the following key points:\n",
        "\n",
        "* **Integrated Healthcare Ecosystem - “All-in-One” Advantage:** CVS's unique combination of assets (pharmacy network, PBM, insurance, clinics) positions it to benefit from the industry's shift to integrated, value-based care. The company can capture revenue at multiple points in the healthcare value chain and use data across its businesses to improve efficiency. This model creates opportunities for cross-selling and cost savings - for example, steering Aetna members to CVS pharmacies/clinics or using PBM data to manage medical risk for insurance customers. CVS is effectively building a healthcare ecosystem that competitors will find difficult to replicate at scale. The strategy aligns with macro trends and has the potential to deliver superior outcomes (health improvements that lower overall costs). If successful, CVS could command a stronger competitive moat and customer loyalty (patients stay “in-network” with CVS for many needs). We view this integrated approach as a long-term value driver for the stock, similar to how investors have rewarded UnitedHealth Group's diversified model with a premium valuation. CVS is currently the world's #2 healthcare company by revenue, underscoring that it has the heft to be a major player in reshaping care delivery.\n",
        "\n",
        "* **Market Leadership and Defensive Core Business:** CVS enjoys leading market share in key segments. It fills about 24% of U.S. retail prescriptions (vs \\~18% for Walgreens) and thus wields considerable bargaining power with drug manufacturers and health plans. The sheer scale of \\~300,000 employees and 70+ million loyalty program members gives CVS a massive platform to implement initiatives (ex. Rolling out new health services or digital tools nationwide). Importantly, the core pharmacy business is relatively defensive - people need medications in any economic climate, and CVS's prescription volume should hold up even in recessions. The addition of primary care clinics (Oak Street) and home health (Signify) further anchors CVS in essential healthcare services that are less discretionary. This defensive quality means CVS generates strong cash flows and can weather macroeconomic volatility better than many industries. Competitor retrenchment also plays into CVS's hand: Rite Aid's bankruptcy and store closures will likely send a portion of their prescription volume to CVS by default, boosting CVS's same-store sales without requiring costly customer acquisition. Likewise, smaller independent pharmacies continue to struggle, which often drives prescription business toward the big PBMs and chains like CVS. Overall, CVS's entrenched position in an oligopolistic industry (retail pharmacy & PBM) provides a stable earnings base and a barrier to new entrants.\n",
        "\n",
        "* **Earnings Growth and Synergy Realization:** After a period of heavy investment, CVS is poised to translate its acquisitions into accelerated earnings growth over the next 2-3 years. Management has explicitly guided to an EPS ramp from \\~8.80 USD in 2023 to \\10 USD in 2025, implying an 8-9% CAGR, which is solid for a mature company. This forecast factors in known headwinds (2024 Medicare plan rating impacts and the loss of a large PBM client, Centene) and still shows growth - indicating confidence in underlying business momentum. Furthermore, the Oak Street and Signify deals are expected to contribute meaningfully by 2025 and beyond. CVS estimates \\$500+ million in cost and revenue synergies from these acquisitions. The company also aims for an incremental 200 bps increase in long-term operating income growth due to these moves. We believe these targets are reasonable given CVS's track record with Aetna (they exceeded initial cost synergy goals post-merger). Early signs are encouraging: Oak Street Health's expansion to 300 centers by 2026, each targeting \\~7M USD EBITDA at maturity, could embed \\~2B USD EBITDA run-rate. If CVS executes on integration, we could see above-trend earnings growth in the later 2020s. In the nearer term, recent quarterly results underscore improving performance - e.g., in Q1 2025 CVS's adjusted operating income rose 54.9% year-on-year (boosted by the absence of prior charges, but even adjusting for that, core growth was strong across segments). This momentum, combined with cost-cutting (CVS announced a plan in late 2022 to reduce corporate expenses and consolidate some store locations), supports the thesis that CVS’s earnings trough is past and a growth inflection is underway.\n",
        "\n",
        "* **Attractive Valuation Relative to Fundamentals:** CVS shares appear undervalued at current levels. The stock trades at roughly 8 times forward earnings, based on the 2024-25 EPS outlook. This is a steep discount to the broader market (S&P 500 forward P/E \\~17-18) and also cheaper than pure healthcare peers (the healthcare sector average P/E is often in the mid-teens). Even allowing for the company's higher debt, the valuation seems to price in an overly pessimistic scenario. Our simple valuation check: using management's 2025 EPS target of \\~10 USD and a conservative P/E of 12x (below the market average), yields a stock value of \\$120 - significantly above the recent trading range in the $70s. In other words, there is potential for 50% upside if CVS can deliver on earnings and close part of the valuation gap. Cash flow metrics also indicate a bargain: CVS's free cash flow yield is high-single-digits percentage, and it continues to return cash via dividends (\\$2.42 per share annually). We acknowledge some of the discount is due to debt load and integration risk, but CVS is actively paying down debt and maintaining solid credit ratings. With EBITDA improving and no near-term liquidity issues, we believe the debt is manageable. As synergies are realized and earnings grow, investors could re-rate the stock upwards. Additionally, once integration costs subside, CVS may resume buybacks, which would further bolster EPS and the stock price. The risk/reward skews positive at this valuation - there is a margin of safety given the stable core business, while any outperformance (or even just hitting guidance) could catalyze multiple expansion from the current depressed level.\n",
        "\n",
        "* **Improving Healthcare Tailwinds and Policy Support:** Finally, the macro-environment for CVS's business is arguably set to improve. The worst of the pandemic disruptions are over, and healthcare utilization patterns are normalizing in a way that benefits CVS (more doctor visits and prescriptions, whereas 2020-2021 had disruptions). There is also growing policy support for approaches that CVS can capitalize on - for instance, federal encouragement of value-based care models in Medicare Advantage (where Aetna is big) and increased reimbursement for preventive services (which CVS's clinics provide). Regulatory pressure on drug pricing could squeeze manufacturers or smaller pharmacies more than CVS, which has the scale to negotiate and diversify revenue. In short, healthcare spending will continue to rise, and payors/government want more cost-effective care delivery; CVS's strategy aligns with providing lower-cost care in retail and home settings (as opposed to expensive hospital care), so it stands to gain volume. Moreover, as millions of baby boomers age into Medicare, CVS's integrated offering (insurance + convenient care + pharmacy) is well-positioned to capture a good share of that demographic through Aetna's plans and services. These secular tailwinds support a long-term growth thesis for CVS, beyond the immediate financial considerations.\n",
        "\n",
        "**Key Risks:** It is important to note a few risks to our thesis. Integration of large acquisitions can be challenging - if Oak Street or Signify underperform or face cultural clashes within CVS, the expected benefits may not materialize. Regulatory changes are a wildcard: aggressive government action on PBM practices or drug pricing could impact CVS's margins in the pharmacy business. Competition from innovative players (Amazon, tech-driven care models) could gradually chip away at parts of CVS's empire if the company becomes complacent. Lastly, the debt load, while manageable, reduces financial flexibility if business were to unexpectedly deteriorate. We believe these risks are real but manageable, and that CVS’s management has shown prudence (for instance, exiting the ACA exchanges to stem losses demonstrates discipline in focusing on profitable avenues). The current stock price already reflects a fair degree of concern, whereas successful execution could alleviate these worries and drive a revaluation. In conclusion, the investment thesis is that CVS Health is a fundamentally strong, cash-generative business at the center of a transforming healthcare system, and the market is undervaluing its earnings power and strategic assets. The company's leadership in pharmacy and bold expansion into care delivery give it multiple avenues for growth. With the stock trading at an attractive valuation, we see a compelling opportunity for upside as the integration story progresses and financial results improve.\n"
      ],
      "metadata": {
        "id": "YCFFjin8KtgI"
      },
      "id": "YCFFjin8KtgI"
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "GmK81EfiJxr3"
      },
      "source": [
        "# Technical Analysis"
      ],
      "id": "GmK81EfiJxr3"
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Valuation - P/E Ratio Comparison\n",
        "First, we calculate CVS's forward Price/Earnings ratio using management's earnings guidance. This helps illustrate how the market is valuing CVS relative to its expected profits."
      ],
      "metadata": {
        "id": "nJxgTeH_6M3k"
      },
      "id": "nJxgTeH_6M3k"
    },
    {
      "cell_type": "code",
      "source": [
        "pip install yfinance"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gJ_xXJzq6mmI",
        "outputId": "e406187f-6f2e-439e-9014-9833b1f6d04e"
      },
      "id": "gJ_xXJzq6mmI",
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: yfinance in /usr/local/lib/python3.11/dist-packages (0.2.65)\n",
            "Requirement already satisfied: pandas>=1.3.0 in /usr/local/lib/python3.11/dist-packages (from yfinance) (2.2.2)\n",
            "Requirement already satisfied: numpy>=1.16.5 in /usr/local/lib/python3.11/dist-packages (from yfinance) (2.0.2)\n",
            "Requirement already satisfied: requests>=2.31 in /usr/local/lib/python3.11/dist-packages (from yfinance) (2.32.3)\n",
            "Requirement already satisfied: multitasking>=0.0.7 in /usr/local/lib/python3.11/dist-packages (from yfinance) (0.0.11)\n",
            "Requirement already satisfied: platformdirs>=2.0.0 in /usr/local/lib/python3.11/dist-packages (from yfinance) (4.3.8)\n",
            "Requirement already satisfied: pytz>=2022.5 in /usr/local/lib/python3.11/dist-packages (from yfinance) (2025.2)\n",
            "Requirement already satisfied: frozendict>=2.3.4 in /usr/local/lib/python3.11/dist-packages (from yfinance) (2.4.6)\n",
            "Requirement already satisfied: peewee>=3.16.2 in /usr/local/lib/python3.11/dist-packages (from yfinance) (3.18.2)\n",
            "Requirement already satisfied: beautifulsoup4>=4.11.1 in /usr/local/lib/python3.11/dist-packages (from yfinance) (4.13.4)\n",
            "Requirement already satisfied: curl_cffi>=0.7 in /usr/local/lib/python3.11/dist-packages (from yfinance) (0.12.0)\n",
            "Requirement already satisfied: protobuf>=3.19.0 in /usr/local/lib/python3.11/dist-packages (from yfinance) (5.29.5)\n",
            "Requirement already satisfied: websockets>=13.0 in /usr/local/lib/python3.11/dist-packages (from yfinance) (15.0.1)\n",
            "Requirement already satisfied: soupsieve>1.2 in /usr/local/lib/python3.11/dist-packages (from beautifulsoup4>=4.11.1->yfinance) (2.7)\n",
            "Requirement already satisfied: typing-extensions>=4.0.0 in /usr/local/lib/python3.11/dist-packages (from beautifulsoup4>=4.11.1->yfinance) (4.14.1)\n",
            "Requirement already satisfied: cffi>=1.12.0 in /usr/local/lib/python3.11/dist-packages (from curl_cffi>=0.7->yfinance) (1.17.1)\n",
            "Requirement already satisfied: certifi>=2024.2.2 in /usr/local/lib/python3.11/dist-packages (from curl_cffi>=0.7->yfinance) (2025.7.14)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.11/dist-packages (from pandas>=1.3.0->yfinance) (2.9.0.post0)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.11/dist-packages (from pandas>=1.3.0->yfinance) (2025.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.11/dist-packages (from requests>=2.31->yfinance) (3.4.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.11/dist-packages (from requests>=2.31->yfinance) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.11/dist-packages (from requests>=2.31->yfinance) (2.4.0)\n",
            "Requirement already satisfied: pycparser in /usr/local/lib/python3.11/dist-packages (from cffi>=1.12.0->curl_cffi>=0.7->yfinance) (2.22)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.11/dist-packages (from python-dateutil>=2.8.2->pandas>=1.3.0->yfinance) (1.17.0)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import yfinance as yf\n",
        "\n",
        "ticker = yf.Ticker(\"CVS\")\n",
        "data = ticker.history(period=\"1d\")\n",
        "current_price = data[\"Close\"].iloc[-1]\n",
        "\n",
        "print(f\"CVS stock price (latest close): ${current_price:.2f}\")\n",
        "\n",
        "# Forward P/E calculation for CVS\n",
        "eps_2025_proj = 10.0   # projected 2025 EPS (adjusted) from CVS guidance\n",
        "\n",
        "forward_pe = current_price / eps_2025_proj\n",
        "print(f\"CVS forward P/E based on 2025 EPS = {forward_pe:.1f}x\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "k8R5YL8O6L1a",
        "outputId": "2b2b0e1c-e412-49b1-be5e-79d228aa72a6"
      },
      "id": "k8R5YL8O6L1a",
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CVS stock price (latest close): $61.96\n",
            "CVS forward P/E based on 2025 EPS = 6.2x\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "This roughly 6.2x forward P/E underscores our point that CVS is trading at a steep discount. For context, we compare this to a competitor and the market:"
      ],
      "metadata": {
        "id": "fVevYiyu6TlO"
      },
      "id": "fVevYiyu6TlO"
    },
    {
      "cell_type": "code",
      "source": [
        "def get_pe(ticker):\n",
        "    tk = yf.Ticker(ticker)\n",
        "    info = tk.info\n",
        "    return {\n",
        "        \"symbol\": ticker,\n",
        "        \"forwardPE\": info.get(\"forwardPE\"),\n",
        "        \"trailingPE\": info.get(\"trailingPE\")\n",
        "    }\n",
        "\n",
        "wba_pe = get_pe(\"WBA\")\n",
        "spy_pe = get_pe(\"SPY\")\n",
        "xlv_pe = get_pe(\"XLV\")\n",
        "\n",
        "print(\"Walgreens (WBA) P/E ratios:\", wba_pe)\n",
        "print(\"SPY (S&P 500 ETF) P/E ratios:\", spy_pe)\n",
        "print(\"XLV (Health Care Select Sector SPDR ETF) P/E ratios:\", xlv_pe)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pz1KHnIW7IR3",
        "outputId": "c6902d67-e5c7-43be-d6a7-c2ae3b1dd424"
      },
      "id": "pz1KHnIW7IR3",
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Walgreens (WBA) P/E ratios: {'symbol': 'WBA', 'forwardPE': 7.816326, 'trailingPE': None}\n",
            "SPY (S&P 500 ETF) P/E ratios: {'symbol': 'SPY', 'forwardPE': None, 'trailingPE': 27.128555}\n",
            "XLV (Health Care Select Sector SPDR ETF) P/E ratios: {'symbol': 'XLV', 'forwardPE': None, 'trailingPE': 23.404016}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "* Walgreens (WBA) is trading around 7.8x forward earnings (reflecting its own challenges).\n",
        "* The S&P 500 is around 27x, and the healthcare sector average P/E is around 23x.\n",
        "\n",
        "CVS's discount relative to the market is evident. Even allowing for some execution risk, a forward multiple below 8x is low for a company with CVS's stable businesses and mid-single-digit growth prospects. If CVS were to be valued at, say, 12x forward earnings (still below peers), the stock would be around \\$120 (12 x \\$10 EPS), as noted earlier. This simple calculation supports our view that valuation re-rating could drive significant upside if CVS delivers on its earnings trajectory."
      ],
      "metadata": {
        "id": "D1kEReSz70Gm"
      },
      "id": "D1kEReSz70Gm"
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Option Pricing - Black-Scholes Model\n",
        "\n"
      ],
      "metadata": {
        "id": "GGLNFheg79yW"
      },
      "id": "GGLNFheg79yW"
    },
    {
      "cell_type": "markdown",
      "source": [
        "Next, we turn to the options strategy. We consider an August 2025 call option on CVS stock as our investment vehicle. To ensure we understand its pricing, we use the Black-Scholes option pricing model. Specifically, we price a call option that expires around August 31, 2025 (roughly 45 days from now, covering the Q2 earnings release in early August).\n",
        "\n",
        "We look at a call with various strike prices (currently the stock is around \\$62). Key inputs to Black-Scholes include the current stock price (S), strike (K), time to expiration (T), risk-free rate (r), and volatility (σ)."
      ],
      "metadata": {
        "id": "rovgT6sn9Rab"
      },
      "id": "rovgT6sn9Rab"
    },
    {
      "cell_type": "code",
      "source": [
        "import math\n",
        "\n",
        "#K = strike, sigma = implied volatility\n",
        "def cvs_black_scholes_call(K, sigma):\n",
        "  #Parameters\n",
        "  S = 61.96   # current stock price\n",
        "  T = 0.123  # time to expiration in years (~45 days)\n",
        "  r = 0.0444   # risk-free interest rate (4.44%) based on 10 Year T-Rate\n",
        "\n",
        "  # Black-Scholes calculation for call option\n",
        "  d1 = (math.log(S/K) + (r + 0.5 * sigma**2) * T) / (sigma * math.sqrt(T))\n",
        "  d2 = d1 - sigma * math.sqrt(T)\n",
        "\n",
        "  # Cumulative normal distribution function (using math.erf for approximation)\n",
        "  N = lambda x: 0.5 * (1 + math.erf(x / math.sqrt(2)))\n",
        "\n",
        "  call_price = S * N(d1) - K * math.exp(-r*T) * N(d2)\n",
        "  return call_price\n",
        "\n",
        "import math\n",
        "\n",
        "def cvs_black_scholes_put(K, sigma):\n",
        "    # Parameters\n",
        "    S = 61.96\n",
        "    T = 0.123\n",
        "    r = 0.0444\n",
        "\n",
        "    # Black-Scholes calculation for d1 and d2\n",
        "    d1 = (math.log(S / K) + (r + 0.5 * sigma**2) * T) / (sigma * math.sqrt(T))\n",
        "    d2 = d1 - sigma * math.sqrt(T)\n",
        "\n",
        "    # Cumulative normal distribution function (using math.erf for approximation)\n",
        "    N = lambda x: 0.5 * (1 + math.erf(x / math.sqrt(2)))\n",
        "\n",
        "    # Put option price formula\n",
        "    put_price = K * math.exp(-r * T) * N(-d2) - S * N(-d1)\n",
        "    return put_price\n",
        "\n",
        "ticker = yf.Ticker(\"CVS\")\n",
        "\n",
        "# List all expiration dates to find the exact string for August 29\n",
        "expirations = ticker.options\n",
        "print(\"Available Expirations:\", expirations)\n",
        "\n",
        "# Filter for August 29, 2025 expiration\n",
        "target_exp = None\n",
        "for exp in expirations:\n",
        "    if \"2025-08-29\" in exp:\n",
        "        target_exp = exp\n",
        "        break\n",
        "\n",
        "if target_exp is None:\n",
        "    print(\"August 29, 2025 expiration not found.\")\n",
        "else:\n",
        "    print(f\"\\nUsing expiration date: {target_exp}\")\n",
        "    option_chain = ticker.option_chain(target_exp)\n",
        "    calls = option_chain.calls\n",
        "\n",
        "    puts = option_chain.puts\n",
        "\n",
        "    # Create a dictionary mapping contractSymbol to strike, lastPrice, impliedVolatility\n",
        "    call_data = {}\n",
        "    for _, row in calls.iterrows():\n",
        "        call_data[row['contractSymbol']] = {\n",
        "            'strike': row['strike'],\n",
        "            'lastPrice': row['lastPrice'],\n",
        "            'impliedVolatility': row['impliedVolatility']\n",
        "        }\n",
        "\n",
        "    put_data = {}\n",
        "    for _, row in puts.iterrows():\n",
        "        put_data[row['contractSymbol']] = {\n",
        "            'strike': row['strike'],\n",
        "            'lastPrice': row['lastPrice'],\n",
        "            'impliedVolatility': row['impliedVolatility']\n",
        "        }\n",
        "\n",
        "for contract, data in call_data.items():\n",
        "  print(\n",
        "    f\"\\nBlack-Scholes estimated call option price (strike ${data['strike']}, exp Aug 29 2025) = \"\n",
        "    f\"${cvs_black_scholes_call(data['strike'], data['impliedVolatility']):.2f};\\n\"\n",
        "    f\"premium is ${data['lastPrice']}, difference of \"\n",
        "    f\"${cvs_black_scholes_call(data['strike'], data['impliedVolatility']) - data['lastPrice']:.2f}\"\n",
        ")\n",
        "\n",
        "for contract, data in put_data.items():\n",
        "  print(\n",
        "    f\"\\nBlack-Scholes estimated put option price (strike ${data['strike']}, exp Aug 29 2025) = \"\n",
        "    f\"${cvs_black_scholes_put(data['strike'], data['impliedVolatility']):.2f};\\n\"\n",
        "    f\"premium is ${data['lastPrice']}, difference of \"\n",
        "    f\"${cvs_black_scholes_put(data['strike'], data['impliedVolatility']) - data['lastPrice']:.2f}\"\n",
        ")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5KmcAPd98U3P",
        "outputId": "abd80413-e42a-4076-9bcd-72ba8b73856e"
      },
      "id": "5KmcAPd98U3P",
      "execution_count": 36,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Available Expirations: ('2025-07-25', '2025-08-01', '2025-08-08', '2025-08-15', '2025-08-22', '2025-08-29', '2025-09-19', '2025-10-17', '2025-11-21', '2026-01-16', '2026-02-20', '2026-03-20', '2026-06-18', '2026-09-18', '2026-12-18', '2027-01-15')\n",
            "\n",
            "Using expiration date: 2025-08-29\n",
            "\n",
            "Black-Scholes estimated call option price (strike $62.0, exp Aug 29 2025) = $3.12;\n",
            "premium is $2.79, difference of $0.33\n",
            "\n",
            "Black-Scholes estimated call option price (strike $63.0, exp Aug 29 2025) = $2.77;\n",
            "premium is $2.3, difference of $0.47\n",
            "\n",
            "Black-Scholes estimated call option price (strike $65.0, exp Aug 29 2025) = $1.97;\n",
            "premium is $2.21, difference of $-0.24\n",
            "\n",
            "Black-Scholes estimated call option price (strike $66.0, exp Aug 29 2025) = $1.55;\n",
            "premium is $1.26, difference of $0.29\n",
            "\n",
            "Black-Scholes estimated put option price (strike $55.0, exp Aug 29 2025) = $0.83;\n",
            "premium is $0.77, difference of $0.06\n",
            "\n",
            "Black-Scholes estimated put option price (strike $85.0, exp Aug 29 2025) = $23.64;\n",
            "premium is $21.01, difference of $2.63\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "We first note that 65 call is overpriced, and selling this would be advantageous to us. While the 85 put is notably underpriced, the stock price jumping from 62 to 85 dollars in 45 days is very unlikely, especially given that the 6 month peak in CVS's stock price was 70 dollars per share.\n",
        "\n",
        "We are leaning towards a bull call spread because of the existence of an overpriced call, bullish outlook but not extremely bullish because of the 45 day time frame, and my personal preference to be a little risk averse.\n",
        "\n",
        "The breakeven for 62/65 bull call spread would be 62+2.79-2.21= 62.58, while the breakeven for 63/65 would be 63+2.3-2.21 = 63.09. Being a little more risk averse, we are going for the 62/65 bull call spread."
      ],
      "metadata": {
        "id": "MCVvUDRzDWuW"
      },
      "id": "MCVvUDRzDWuW"
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "# Parameters\n",
        "lower_strike = 62\n",
        "upper_strike = 65\n",
        "premium_buy = 2.79   # premium paid for 62 call\n",
        "premium_sell = 2.21  # premium received for 65 call\n",
        "net_debit = premium_buy - premium_sell\n",
        "\n",
        "# Define a range of underlying stock prices at expiration\n",
        "S = np.linspace(55, 75, 400)\n",
        "\n",
        "# Calculate payoff for long call (62 strike)\n",
        "payoff_long_call = np.maximum(S - lower_strike, 0) - premium_buy\n",
        "\n",
        "# Calculate payoff for short call (65 strike)\n",
        "payoff_short_call = premium_sell - np.maximum(S - upper_strike, 0)\n",
        "\n",
        "# Bull call spread payoff = payoff_long_call + payoff_short_call\n",
        "payoff_spread = payoff_long_call + payoff_short_call\n",
        "\n",
        "max_loss = net_debit\n",
        "max_gain = (upper_strike - lower_strike) - net_debit\n",
        "breakeven = lower_strike + net_debit\n",
        "\n",
        "# Plotting\n",
        "plt.figure(figsize=(10,6))\n",
        "plt.plot(S, payoff_long_call, label='Long Call (Strike 62)', linestyle='--')\n",
        "plt.plot(S, payoff_short_call, label='Short Call (Strike 65)', linestyle='--')\n",
        "plt.plot(S, payoff_spread, label='Bull Call Spread (62/65)', linewidth=2)\n",
        "plt.axhline(0, color='black', linewidth=0.8)\n",
        "plt.axvline(lower_strike, color='gray', linestyle=':')\n",
        "plt.axvline(upper_strike, color='gray', linestyle=':')\n",
        "plt.title('Profit Diagram for 62/65 Bull Call Spread')\n",
        "plt.xlabel('Stock Price at Expiration ($)')\n",
        "plt.ylabel('Profit ($)')\n",
        "plt.legend()\n",
        "plt.grid(True)\n",
        "plt.show()\n",
        "\n",
        "print(f\"Maximum Loss (net premium): ${max_loss:.2f}\")\n",
        "print(f\"Maximum Gain (spread width - net premium): ${max_gain:.2f}\")\n",
        "print(f\"Breakeven Stock Price at Expiration: ${breakeven:.2f}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 616
        },
        "id": "ylfNAGigF8x_",
        "outputId": "a9380e65-b805-46f9-f467-e6bf56a7ee1f"
      },
      "id": "ylfNAGigF8x_",
      "execution_count": 39,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Maximum Loss (net premium): $0.58\n",
            "Maximum Gain (spread width - net premium): $2.42\n",
            "Breakeven Stock Price at Expiration: $62.58\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "In our case, because we believe there is significant upside potential and the calls are relatively cheap, we would normally favor a straightforward long call to retain unlimited upside. However, due to my personal preference of being risk averse, I have chosen the bull call spread as an alternative to lower cost.\n",
        "\n",
        "Also, CVS is expected to report Q2 2025 earnings in the first week of August. The option covers that event, allowing us to benefit from any post-earnings stock jump. We'll monitor implied volatility going into earnings - often it rises, inflating option prices (the so-called volatility crush happens after earnings). Since we have already purchased the call, rising IV pre-earnings actually benefits us (we could even take profits before expiration if the option premium spikes). If there were more call options that had higher call prices, they would be put into consideration, but as of right now, the ones we explored are the only ones in the options market."
      ],
      "metadata": {
        "id": "1m7pkBj3GT2y"
      },
      "id": "1m7pkBj3GT2y"
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Final Recommendation\n",
        "\n",
        "**Strategy:** Based on the above analysis, I recommend a bull call spread on CVS Health, targeting an August 29 2025 expiry. Specifically, buy the CVS August 29, 2025 call with a strike price of \\$62 and sell the call with a strike price of \\$65.\n",
        "\n",
        "This strategy aligns with the positive outlook as well as the limitations of the 45 day to maturity time frame and offers leveraged exposure to a stock price increase, while limiting downside risk to the premium paid.\n",
        "\n",
        "**Rationale:** CVS's fundamentals and valuation make a compelling case for upside, yet the stock has been trading in a range, possibly awaiting a catalyst. We identify the upcoming earnings (and potentially any new strategic updates) as a catalyst that could bridge the valuation gap. By using a bull call spread, we risk only a small, fixed amount of capital (premium) instead of buying the stock outright. If our thesis is correct and CVS's stock moves up, the percentage return on the option will far exceed the return from owning the shares. This leveraged return is attractive given the strong probability we assign to CVS delivering a good quarter and maintaining its 2024 guidance. We choose the late August expiration to ensure the position remains active through the Q2 earnings release and a few weeks after, allowing the market time to absorb and react to the news. The selection of the strike prices are reflecting optimism but not overly aggressive (roughly the upper end of CVS's trading range in recent months). This strike keeps the premium affordable as per Black-Scholes pricing, which means the capital at risk is modest.\n",
        "\n",
        "In terms of trade management:\n",
        "\n",
        "* **Entry:** The recommended entry is to buy the calls ahead of the earnings report (ideally several weeks before, like now) while implied volatility is at a normal level. We anticipate IV will rise as earnings approach, which could increase the option's market value even before any stock movement.\n",
        "\n",
        "* **Position Size**: We should size the option position appropriately, considering worst-case loss of 100% of the premium. This could be, say, 1-2% of a portfolio for a speculative call position on a single stock.\n",
        "\n",
        "* **Exit Plan:** The base case is to hold through the earnings announcement. If CVS's earnings significantly beat expectations or other positive news emerges (ex. Favorable regulatory news or an acceleration of share buybacks), the stock could jump and we would then evaluate our calls again. Conversely, if the earnings outcome is disappointing or the stock stagnates, the calls will lose value. In that scenario, since the maximum loss is capped, we might hold the calls to expiration (in case a late-August rebound occurs) or cut loss earlier if we conclude the thesis is impaired. Essentially, we accept the binary nature: either the thesis is validated (stock up and we profit) or it isn't (option expires worthless). Either way, we are still being risk averse to an extent.\n",
        "\n",
        "* **Alternate Strategies Considered:** We considered a bullish strategy using the stock itself (going long CVS shares) or selling put options (to potentially acquire the stock at a lower cost basis). While those are viable for a long-term investor, they tie up more capital and don't offer the high upside/low downside profile of the call. We also can consider a protective collar or covered call approach for a hypothetical existing CVS position. However, since this report is aimed at profit generation rather than hedging, we favor the outright long call.\n",
        "\n",
        "* **Why We Are Confident:** In summary, our recommendation stems from confidence in CVS's undervalued status and improving prospects. The stock's current mispricing of trading at 6x earnings - provides a cushion, and any confirmation of positive trends (earnings growth, successful integration of acquisitions, etc.) could drive a quick re-rating. CVS's diversified revenue streams and defensive characteristics mean that even if the broad market faces volatility, CVS may hold up (or even attract defensive rotation). Our strategy allows us to capture that potential upside through the earnings event but also protects us from a potential downside."
      ],
      "metadata": {
        "id": "uXY6HJmaLxjh"
      },
      "id": "uXY6HJmaLxjh"
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "kKBRcpx5Jxr4"
      },
      "source": [
        "# Results\n",
        "TO BE DETERMINED!"
      ],
      "id": "kKBRcpx5Jxr4"
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Next Steps\n",
        "\n",
        "TO BE DETERMINED!"
      ],
      "metadata": {
        "id": "lXV9UkqTMG99"
      },
      "id": "lXV9UkqTMG99"
    }
  ],
  "metadata": {
    "title": "Apple Inc. (AAPL) - Comprehensive Analysis & 12-Month Outlook",
    "company": "Apple Inc.",
    "ticker": "AAPL",
    "industry": "Technology",
    "date": "2024-11-15",
    "summary": "Apple shows strong fundamentals with iPhone 15 cycle momentum and Services growth. Despite macro headwinds, innovation pipeline and loyal customer base support bullish outlook.",
    "prediction": "bullish",
    "targetPrice": 195,
    "currentPrice": 175,
    "tags": [
      "technology",
      "consumer electronics",
      "services",
      "warren buffett"
    ],
    "colab": {
      "provenance": [],
      "toc_visible": true
    },
    "language_info": {
      "name": "python"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 5
}